Monitoring clone dynamics and reversibility in clonal haematopoiesis and myelodysplastic neoplasm associated with PARP inhibitor therapy-a role for early monitoring and intervention.

"Competing interests REM: Consultancy fees: MSD, GSK, AZD, Ellipses, Shionogi and Clovis Oncology. Speakers’ bureau: Roche, GSK, AZD and Clovis Oncology. Travel grants: AZD and GSK. Trial funding: MSD. JL: Advisory board fees from Artios Pharma, AstraZeneca, Bristol Myers Squibb, Eisai, GlaxoSmithKline, Merck Sharp & Dohme Corp, Nuvation. Steering/Data Monitoring Committee fees from Pfizer; Regeneron. Lecture fees from AstraZeneca, GlaxoSmithKline, and Neopharm; Clovis Oncology and Merck Sharp & Dohme Corp; Eisai. Institutional grants from AstraZeneca and MSD/Merck."

"EP is funded by the Cancer Research UK Advanced Clinician Scientist award A24873. MRM is funded through a Great Ormond Street Childrens Charity Professorship. ML is funded by the Cancer Research UK Advanced Clinician Scientist Fellowship (C41405/A19694). ENM is funded by the Medical Research Council (grant reference MR/X001423/1). JL is funded through investigator grants from MSD and AstraZeneca."